BluePrint molecular subtypes predict response to neoadjuvant pertuzumab in HER2-positive breast cancer

[1]  W. Audeh,et al.  Genomic Classification of HER2-Positive Patients With 80-Gene and 70-Gene Signatures Identifies Diversity in Clinical Outcomes With HER2-Targeted Neoadjuvant Therapy , 2022, JCO precision oncology.

[2]  A. Glas,et al.  BluePrint breast cancer molecular subtyping recognizes single and dual subtype tumors with implications for therapeutic guidance , 2022, Breast Cancer Research and Treatment.

[3]  J. Wesseling,et al.  Efficacy of neoadjuvant treatment with or without pertuzumab in patients with stage II and III HER2-positive breast cancer: a nationwide cohort analysis of pathologic response and 5-year survival , 2022, Breast.

[4]  Sung-Bae Kim,et al.  Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer , 2022, New England Journal of Medicine.

[5]  S. Linn,et al.  Three-Year Follow-up of Neoadjuvant Chemotherapy With or Without Anthracyclines in the Presence of Dual ERBB2 Blockade in Patients With ERBB2-Positive Breast Cancer: A Secondary Analysis of the TRAIN-2 Randomized, Phase 3 Trial. , 2021, JAMA oncology.

[6]  F. Marmé,et al.  Chemotherapy de-escalation using an 18F-FDG-PET-based pathological response-adapted strategy in patients with HER2-positive early breast cancer (PHERGain): a multicentre, randomised, open-label, non-comparative, phase 2 trial. , 2021, The Lancet. Oncology.

[7]  E. Winer,et al.  Updated Results of TBCRC026: Phase II Trial Correlating Standardized Uptake Value With Pathological Complete Response to Pertuzumab and Trastuzumab in Breast Cancer , 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  R. Bernards,et al.  Abstract PD3-01: BluePrint performance in predicting pertuzumab benefit in genomically HER2-positive patients: A biomarker analysis of the APHINITY trial , 2021 .

[9]  R. Gelber,et al.  Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer in the APHINITY Trial: 6 Years' Follow-Up , 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  A. Glas,et al.  BluePrint molecular subtyping recognizes single and dual subtype tumors with consequences for therapeutic guidance , 2020 .

[11]  N. Harbeck,et al.  De-escalated chemotherapy versus endocrine therapy plus pertuzumab+ trastuzumab for HR+/HER2+ early breast cancer (BC): First efficacy results from the neoadjuvant WSG-TP-II study. , 2020 .

[12]  A. Witteveen,et al.  Performance Characteristics of the BluePrint® Breast Cancer Diagnostic Test , 2020, Translational oncology.

[13]  Charles M. Perou,et al.  HER2-enriched subtype and pathological complete response in HER2-positive breast cancer: A systematic review and meta-analysis. , 2020, Cancer treatment reviews.

[14]  Sung-Bae Kim,et al.  Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer. , 2019, The New England journal of medicine.

[15]  F. Cardoso,et al.  Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

[16]  E. Perez,et al.  Cost-Effectiveness Analysis of Pertuzumab With Trastuzumab and Chemotherapy Compared to Trastuzumab and Chemotherapy in the Adjuvant Treatment of HER2-Positive Breast Cancer in the United States. , 2019, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[17]  P. Fasching,et al.  Trastuzumab Emtansine for Residual Invasive HER2‐Positive Breast Cancer , 2019, The New England journal of medicine.

[18]  S. Linn,et al.  Neoadjuvant chemotherapy with or without anthracyclines in the presence of dual HER2 blockade for HER2-positive breast cancer (TRAIN-2): a multicentre, open-label, randomised, phase 3 trial. , 2018, The Lancet. Oncology.

[19]  R. Schiff,et al.  De-escalation of treatment in HER2-positive breast cancer: Determinants of response and mechanisms of resistance. , 2017, Breast.

[20]  S. Linn,et al.  Toxicity of dual HER2-blockade with pertuzumab added to anthracycline versus non-anthracycline containing chemotherapy as neoadjuvant treatment in HER2-positive breast cancer: The TRAIN-2 study. , 2016, Breast.

[21]  Y. Yarden,et al.  The combination of trastuzumab and pertuzumab administered at approved doses may delay development of trastuzumab resistance by additively enhancing antibody-dependent cell-mediated cytotoxicity , 2016, mAbs.

[22]  Paolo Morandi,et al.  5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trial. , 2016, The Lancet. Oncology.

[23]  John M S Bartlett,et al.  Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. , 2014, Archives of pathology & laboratory medicine.

[24]  A. Schneeweiss,et al.  Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA). , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

[25]  Jason S. Carroll,et al.  A diagnostic gene profile for molecular subtyping of breast cancer associated with treatment response , 2012, Breast Cancer Research and Treatment.

[26]  Stef van Buuren,et al.  MICE: Multivariate Imputation by Chained Equations in R , 2011 .

[27]  Gary King,et al.  MatchIt: Nonparametric Preprocessing for Parametric Causal Inference , 2011 .

[28]  Werner Scheuer,et al.  Strongly enhanced antitumor activity of trastuzumab and pertuzumab combination treatment on HER2-positive human xenograft tumor models. , 2009, Cancer research.

[29]  A. Nobel,et al.  Supervised risk predictor of breast cancer based on intrinsic subtypes. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  M. Casparie,et al.  Pathology Databanking and Biobanking in The Netherlands, a Central Role for PALGA, the Nationwide Histopathology and Cytopathology Data Network and Archive , 2007, Cellular oncology : the official journal of the International Society for Cellular Oncology.

[31]  P. Ellis,et al.  Adjuvant trastuzumab for HER2-positive breast cancer , 2005, The Lancet.

[32]  A. Schneeweiss,et al.  Long-term efficacy analysis of the randomised, phase II TRYPHAENA cardiac safety study: Evaluating pertuzumab and trastuzumab plus standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer. , 2018, European journal of cancer.

[33]  Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer. , 2017, The New England journal of medicine.

[34]  R Core Team,et al.  R: A language and environment for statistical computing. , 2014 .

[35]  Giulia Bianchi,et al.  Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial. , 2012, The Lancet. Oncology.

[36]  Hilde van der Togt,et al.  Publisher's Note , 2003, J. Netw. Comput. Appl..